1. A 44-year-old man is admitted with gram-negative bacterial meningitis following neurosurgical drainage of a brain abscess. His medication record documents a severe IgE-mediated allergy to penicillin (anaphylaxis to amoxicillin five years ago, confirmed by allergist). Cerebrospinal fluid Gram stain shows gram-negative rods. The neurology team asks about antibiotic selection. The infectious disease consultant advises that if carbapenem therapy is ultimately chosen, meropenem is strongly preferred over imipenem-cilastatin for this specific patient in this specific setting. Which of the following best explains the rationale for preferring meropenem over imipenem-cilastatin in this patient with gram-negative meningitis?
A) Meropenem achieves substantially higher CSF (cerebrospinal fluid) concentrations than imipenem due to lower protein binding and greater lipophilicity, making it more effective for CNS infections regardless of seizure risk considerations
B) Meropenem does not require cilastatin co-administration, eliminating the risk of cilastatin-mediated CNS toxicity that occurs when cilastatin crosses a disrupted blood-brain barrier in patients with meningitis
C) Meropenem covers a broader spectrum of gram-negative pathogens causing nosocomial meningitis than imipenem, including organisms with reduced OprD expression that are not covered by imipenem at standard CSF concentrations
D) Meropenem carries substantially lower seizure risk than imipenem because its C-1 beta-methyl group reduces interaction with the GABA-A (gamma-aminobutyric acid type A) receptor picrotoxin-binding site; in a patient with meningitis — where the blood-brain barrier is disrupted, CNS drug exposure is elevated, and baseline neuronal excitability is increased by the infection itself — the lower seizurogenic potential of meropenem is clinically decisive
E) Meropenem is preferred because the penicillin allergy history creates a risk of cross-reactivity with imipenem's thiazolidine ring component, whereas meropenem's absence of a thiazolidine ring eliminates this cross-reactivity concern in a patient with confirmed IgE-mediated penicillin allergy
ANSWER: D
Rationale:
The preference for meropenem over imipenem in CNS infections integrates two pharmacological properties of the CNS setting with one structural difference between these carbapenems. Imipenem carries a recognized risk of lowering the seizure threshold through GABA-A receptor antagonism at the picrotoxin-binding site within the chloride channel; this reduces inhibitory GABAergic neurotransmission and predisposes to seizures, particularly when drug concentrations are elevated. Meropenem's C-1 beta-methyl group at position 1 of the carbapenem ring reduces its affinity for the GABA-A picrotoxin site, producing substantially lower intrinsic seizurogenic potential. In a patient with bacterial meningitis, three factors amplify the relevance of this difference: first, the disrupted blood-brain barrier allows higher CNS drug penetration than in normal cerebral tissue; second, meningitis itself elevates neuronal excitability through cytokine release, cerebral edema, and direct neuronal stress; third, seizures in a neurosurgical patient with a recent brain abscess carry particularly high clinical consequences. The combination of imipenem's inherent GABA-A antagonism with these amplifying factors makes meropenem the clear preference.
Option A: Option A is incorrect; CSF pharmacokinetic differences between meropenem and imipenem are not the primary or decisive basis for this preference — both achieve adequate CSF penetration with inflamed meninges; the seizure risk difference is the clinical rationale.
Option B: Option B is incorrect; cilastatin does not cross the blood-brain barrier in meaningful concentrations and has no identified CNS toxicity mechanism; it is a peripheral renal DHP-I (dehydropeptidase I) inhibitor without CNS activity.
Option C: Option C is incorrect; meropenem and imipenem have broadly overlapping gram-negative spectra for meningitis pathogens, and spectrum differences do not account for the preference in this clinical setting.
Option E: Option E is incorrect; imipenem does not contain a thiazolidine ring — it is a carbapenem with a pyroline ring, not the beta-lactam-thiazolidine bicyclic structure of penicillins; neither imipenem nor meropenem cross-reacts meaningfully with penicillin through bicyclic ring epitopes.
2. A 67-year-old woman is being treated for KPC-producing Klebsiella pneumoniae bacteremia with ceftazidime-avibactam. On day 8 of therapy she develops recurrent fever and repeat blood cultures grow KPC-positive Klebsiella pneumoniae; the repeat isolate is now resistant to ceftazidime-avibactam despite being susceptible at the start of therapy. Molecular testing of the new isolate identifies a KPC D179Y point mutation in the KPC enzyme active site. The infectious disease team needs to select a salvage agent. Which of the following is the most pharmacologically sound next step, and why?
A) Switch to meropenem-vaborbactam, because vaborbactam is a boronic acid inhibitor that forms a tetrahedral adduct with the KPC catalytic serine through a binding mode distinct from avibactam's DBO carbamylation; KPC mutations that confer avibactam resistance (such as D179Y, which destabilizes the avibactam-KPC covalent complex) do not necessarily confer cross-resistance to vaborbactam because the two inhibitors contact overlapping but non-identical residues in the KPC active site
B) Switch to aztreonam-avibactam at double the standard avibactam dose, because higher avibactam concentrations overcome the reduced binding affinity of the D179Y KPC variant; the aztreonam partner provides synergistic PBP3 binding that partially compensates for reduced avibactam inhibitory activity against the mutant KPC
C) Switch to imipenem-cilastatin-relebactam, because relebactam's DBO scaffold shares no structural overlap with avibactam and therefore fully retains inhibitory activity against all KPC variants including D179Y; the structural distinction between relebactam and avibactam guarantees cross-resistance cannot occur
D) Continue ceftazidime-avibactam and add colistin for synergy, because the combination of avibactam (even at reduced activity against D179Y KPC) with colistin-mediated outer membrane disruption provides sufficient periplasmic avibactam accumulation to overcome the mutation's effect on inhibitor binding
E) Switch to cefiderocol monotherapy, because cefiderocol's siderophore uptake mechanism bypasses the periplasmic KPC enzyme entirely by delivering the drug directly to the inner membrane where KPC is not expressed
ANSWER: A
Rationale:
On-therapy emergence of avibactam resistance during treatment of KPC-CRE is a documented clinical phenomenon, typically mediated by point mutations in the KPC enzyme that destabilize the covalent avibactam-KPC acyl-enzyme intermediate. The D179Y substitution is among the most commonly identified avibactam resistance mutations in clinical KPC variants; it alters the geometry of the KPC active site in a way that reduces avibactam's ability to form or maintain a stable carbamyl ester with the catalytic serine. Critically, the resistance mechanism is inhibitor-class-specific: avibactam and vaborbactam, while both targeting the KPC catalytic serine, do so through structurally distinct mechanisms — avibactam forms a covalent carbamyl ester (DBO mechanism), whereas vaborbactam forms a reversible covalent tetrahedral boronate ester (boronic acid mechanism). Because these two inhibitors contact overlapping but non-identical active site residues and use different chemistry, KPC mutations selected under avibactam pressure do not uniformly confer resistance to vaborbactam. Multiple case reports and in vitro studies have documented retained meropenem-vaborbactam susceptibility in KPC variants resistant to ceftazidime-avibactam, and this switch is the standard clinical approach for avibactam-resistant KPC-CRE.
Option B: Option B is incorrect; escalating avibactam dose does not reliably overcome avibactam resistance mutations because the D179Y substitution reduces binding affinity — a pharmacodynamic problem not solved by concentration escalation alone; aztreonam-avibactam uses the same avibactam inhibitor and would be similarly affected.
Option C: Option C is incorrect; while imipenem-relebactam is an alternative, the claim that relebactam guarantees zero cross-resistance to all KPC D179Y variants is overstated — some degree of relebactam resistance has been observed with certain KPC mutations, and the guarantee of no cross-resistance is not established.
Option D: Option D is incorrect; adding colistin to a failing avibactam regimen is not a pharmacologically sound approach to overcoming an enzyme active site mutation; outer membrane disruption by colistin does not restore avibactam binding to a mutant KPC enzyme.
Option E: Option E is incorrect; KPC is a periplasmic enzyme, not an inner membrane enzyme; cefiderocol does reach the periplasm via TonB-dependent transport and is subject to periplasmic KPC hydrolysis; cefiderocol's siderophore mechanism achieves outer membrane penetration but does not bypass KPC once in the periplasm.
3. A 59-year-old woman with type 2 diabetes is discharged on outpatient parenteral antibiotic therapy (OPAT) with ertapenem 1 g IV once daily for complicated pyelonephritis caused by an ESBL-producing Escherichia coli. She was doing well until day 4, when she develops rigors, hypotension, and a temperature of 39.4°C. She is admitted to the emergency department. Repeat blood cultures drawn on admission grow Pseudomonas aeruginosa within 18 hours. The OPAT infectious disease team is called. Which of the following best identifies the most likely explanation for treatment failure and the appropriate immediate therapeutic response?
A) The Pseudomonas aeruginosa bacteremia represents a new, unrelated secondary infection acquired during the OPAT infusion process; ertapenem should be continued for the ESBL E. coli and a second intravenous line should be opened for a separate antipseudomonal agent
B) The treatment failure occurred because ertapenem's high protein binding reduced its free drug concentration below the MIC for ESBL-producing E. coli at the tissue concentrations reached in diabetic patients with reduced peripheral perfusion; the Pseudomonas represents a superinfection due to inadequate urinary tract E. coli clearance
C) Ertapenem lacks reliable activity against Pseudomonas aeruginosa; the patient's urinary tract likely harbored Pseudomonas as a co-pathogen or the Pseudomonas bacteremia emerged from a separate focus, and ertapenem provided no coverage; ertapenem must be replaced with an antipseudomonal carbapenem (meropenem or imipenem-cilastatin) or another antipseudomonal agent active against this isolate
D) Ertapenem treatment failure against the ESBL E. coli occurred because day 4 represents the typical emergence window for ESBL inducible resistance to carbapenems; the Pseudomonas is a co-pathogen that was always present but appeared only once E. coli UTI suppression removed competitive inhibition from the urine
E) The patient developed Pseudomonas bacteremia because ertapenem's DHP-I inhibitor requirement was overlooked, allowing ertapenem to be hydrolyzed in the renal tubule and creating a drug-free urine environment that permitted Pseudomonas overgrowth and subsequent hematogenous seeding
ANSWER: C
Rationale:
The central pharmacological issue in this case is ertapenem's well-characterized and clinically critical coverage gap: it lacks reliable activity against Pseudomonas aeruginosa. Ertapenem's poor affinity for the OprD outer membrane porin used by Pseudomonas for carbapenem entry, combined with rapid efflux by the MexAB-OprM pump, renders ertapenem essentially inactive against this organism. In a diabetic patient with a complicated urinary tract infection and subsequent bacteremia, the possibility that Pseudomonas was present as a co-pathogen in the urinary tract — or emerged from a urinary catheter, vascular line, or another focus — is clinically plausible and represents a recognized OPAT risk. The critical error would be continuing ertapenem and expecting it to address the Pseudomonas bacteremia; escalation to an antipseudomonal carbapenem (meropenem or imipenem-cilastatin) or another agent with confirmed anti-Pseudomonas activity based on susceptibility testing is mandatory. This case exemplifies why ertapenem should not be used empirically when Pseudomonas is a plausible pathogen and why close OPAT follow-up is essential.
Option A: Option A is incorrect; while Pseudomonas can be acquired nosocomially, attributing it entirely to an OPAT line infection without addressing the coverage gap would be clinically dangerous; ertapenem cannot treat the Pseudomonas regardless of source, and continuing it is inadequate.
Option B: Option B is incorrect; ertapenem's pharmacokinetics in diabetic patients do not cause clinically meaningful reductions in free drug concentration against susceptible ESBL E. coli; reduced peripheral perfusion does not explain treatment failure for a drug used in OPAT programs.
Option D: Option D is incorrect; carbapenems are not subject to inducible resistance emergence from ESBL E. coli on this timescale in the manner described; ESBL-producing organisms do not develop carbapenem resistance through the inducible AmpC pathway in a 4-day window.
Option E: Option E is incorrect; ertapenem does not require a DHP-I inhibitor — it is not hydrolyzed by DHP-I and is formulated as a single agent; the absence of cilastatin in ertapenem's formulation is not a clinical error and does not affect renal drug concentrations.
4. A 71-year-old man with stage 5 chronic kidney disease (CrCl 9 mL/min, not yet on dialysis) is admitted with gram-negative bacteremia. The organism is susceptible to both imipenem and meropenem. The admitting team proposes imipenem-cilastatin. The clinical pharmacist intervenes and recommends meropenem instead, citing the patient's renal function as the key reason. Which of the following best explains the pharmacological basis for the pharmacist's recommendation in this specific patient?
A) Meropenem is preferred because it does not require cilastatin co-administration; in a patient with stage 5 CKD, cilastatin itself accumulates to nephrotoxic concentrations and would cause further acute deterioration of the patient's residual renal function
B) Meropenem is preferred because imipenem's renal clearance is so severely impaired in stage 5 CKD that drug accumulation produces plasma and CNS concentrations substantially above those seen with normal renal function; imipenem's GABA-A (gamma-aminobutyric acid type A) receptor antagonism — the mechanism of its seizurogenic effect — is amplified by this accumulation, making the seizure risk unacceptably high in a patient who already has limited physiological reserve; meropenem has the same time-dependent pharmacodynamics but substantially lower intrinsic GABA-A receptor affinity
C) Meropenem is preferred because stage 5 CKD impairs the renal conversion of imipenem to its active antibacterial form; since imipenem is a prodrug that requires renal tubular activation, loss of renal tubular function in advanced CKD renders imipenem pharmacologically inactive
D) Meropenem is preferred because cilastatin competitively inhibits the organic anion transporters responsible for meropenem secretion; in a patient with severe CKD, this drug interaction would prevent meropenem from being co-administered, making imipenem-cilastatin the combination that interferes with alternative drug clearance pathways
E) Meropenem is preferred because imipenem's volume of distribution increases dramatically in severe CKD due to uremic protein displacement, creating unpredictably high free drug fractions that cannot be dose-adjusted reliably; meropenem's lower protein binding makes its free drug fraction more predictable in CKD
ANSWER: B
Rationale:
The pharmacist's recommendation integrates two pharmacological principles: imipenem's seizurogenic mechanism and the effect of renal impairment on drug accumulation. Imipenem is primarily renally eliminated; in a patient with a CrCl of 9 mL/min, drug clearance is severely reduced relative to normal, and even dose-adjusted imipenem regimens may result in substantially higher peak and trough plasma concentrations than anticipated, with proportionally higher CNS drug exposure. Imipenem's mechanism of CNS toxicity — GABA-A receptor antagonism at the picrotoxin-binding site, reducing inhibitory chloride influx and lowering the seizure threshold — is directly concentration-dependent: higher CNS drug concentrations produce greater GABA-A receptor occupancy and greater seizure risk. In advanced CKD without dialysis, the combination of impaired clearance, inability to adjust dosing with precision, and elevated CNS exposure creates a pharmacologically unfavorable risk profile for imipenem. Meropenem, with its C-1 beta-methyl group that substantially reduces GABA-A receptor interaction, carries significantly lower seizure risk at equivalent or even higher plasma concentrations, making it the safer choice in a patient with severe renal impairment.
Option A: Option A is incorrect; cilastatin does not accumulate to nephrotoxic concentrations in CKD; it is a DHP-I (dehydropeptidase I) inhibitor whose renal toxicity is not a recognized clinical concern in CKD patients, and the rationale for avoiding imipenem in this patient is the seizure risk, not cilastatin nephrotoxicity.
Option C: Option C is incorrect; imipenem is not a prodrug requiring renal tubular activation; it is pharmacologically active as administered and its antibacterial activity does not depend on renal conversion.
Option D: Option D is incorrect; cilastatin does not inhibit organic anion transporters responsible for meropenem secretion; this drug interaction does not exist, and the two drugs can be given together without pharmacokinetic interference.
Option E: Option E is incorrect; imipenem has relatively low plasma protein binding (approximately 20%), so uremic protein displacement would not produce dramatically unpredictable free drug fractions; protein binding is not the pharmacokinetic parameter driving the preference for meropenem in this patient.
5. A 24-year-old woman with cystic fibrosis (CF) has been managed with inhaled tobramycin for chronic Pseudomonas aeruginosa airway colonization for four years. She now develops progressive bronchospasm and wheezing with each tobramycin inhalation, confirmed by her pulmonologist as tobramycin inhalation intolerance. Her FEV1 (forced expiratory volume in 1 second) has declined 12% over the past year. The pulmonologist considers alternative inhaled antibiotic options. Which of the following best describes the appropriate alternative and its pharmacological rationale?
A) Switch to inhaled colistin (colistimethate sodium), which provides equivalent Pseudomonas suppression to tobramycin by disrupting Pseudomonas outer membrane lipopolysaccharide; inhaled colistin has a well-established tolerability profile with no bronchospasm risk because its mechanism of action does not involve airway mucosal irritation
B) Switch to intravenous meropenem on a rotating monthly schedule, maintaining the same on-off cycling used with inhaled tobramycin; systemic carbapenems achieve equivalent airway surface liquid concentrations to inhaled aminoglycosides when dosed at extended infusion for Pseudomonas suppression in CF
C) Switch to inhaled azithromycin three times weekly, which achieves direct anti-Pseudomonas activity in CF airways through macrolide disruption of Pseudomonas biofilm quorum sensing; inhaled azithromycin is FDA-approved for Pseudomonas suppression in CF as a direct replacement for inhaled aminoglycosides
D) Discontinue all inhaled antibiotic therapy and initiate oral ciprofloxacin on an alternating monthly schedule, because chronic Pseudomonas colonization in CF does not require sustained suppressive therapy once tobramycin has been administered for four or more years
E) Switch to aztreonam lysine for inhalation (AZLI), which delivers aztreonam directly to the airway surface liquid achieving high local bronchial concentrations against Pseudomonas aeruginosa while minimizing systemic exposure; AZLI is FDA-approved for improving respiratory symptoms in CF patients aged 7 and older with Pseudomonas aeruginosa colonization and provides a well-tolerated alternative to inhaled tobramycin in patients with aminoglycoside intolerance
ANSWER: E
Rationale:
Aztreonam lysine for inhalation (AZLI, marketed as Cayston) is specifically formulated and FDA-approved for the suppressive management of chronic Pseudomonas aeruginosa airway colonization in CF patients. The rationale for inhaled rather than systemic delivery is pharmacokinetic: direct nebulization deposits aztreonam onto the airway surface liquid at concentrations far exceeding those achievable with intravenous therapy, ensuring adequate anti-Pseudomonas drug exposure at the site of infection (the airway biofilm) while maintaining very low systemic drug concentrations, minimizing the systemic adverse effects and toxicities that accumulate with repeated intravenous courses. Aztreonam's gram-negative selective spectrum — specifically its activity against Pseudomonas aeruginosa through PBP3 binding — makes it well-suited for this indication. The lysine salt formulation was developed for appropriate pH compatibility with nebulization solutions. AZLI is a recognized alternative to inhaled tobramycin in patients who cannot tolerate aminoglycoside inhalation.
Option A: Option A is incorrect; while inhaled colistin is used for Pseudomonas suppression in CF as an off-label option, the claim that it carries no bronchospasm risk is incorrect — inhaled colistin is associated with bronchospasm, cough, and chest tightness, and tolerability is not universally superior to tobramycin; it does not represent a clearly superior tolerability alternative.
Option B: Option B is incorrect; intravenous meropenem does not achieve equivalent airway surface liquid concentrations to inhaled aminoglycosides for chronic suppression and is not used on a rotating monthly OPAT schedule for Pseudomonas colonization in CF; systemic carbapenem courses are reserved for acute exacerbations, not chronic suppression.
Option C: Option C is incorrect; azithromycin's benefit in CF is mediated through immunomodulatory and anti-biofilm quorum-sensing disruption rather than direct bactericidal activity, and oral (not inhaled) azithromycin is used in CF; it is not FDA-approved as a direct antibiotic replacement for inhaled aminoglycosides for Pseudomonas suppression.
Option D: Option D is incorrect; chronic suppressive inhaled antibiotic therapy is a cornerstone of CF pulmonary management for patients with established Pseudomonas colonization — discontinuing all suppressive therapy in a patient with declining FEV1 and active colonization is not appropriate care.
6. A 53-year-old man is in the ICU with bacteremia caused by a Klebsiella pneumoniae isolate confirmed by PCR to produce NDM (New Delhi metallo-beta-lactamase). Susceptibility testing shows resistance to all carbapenems, ceftazidime-avibactam, and meropenem-vaborbactam. The isolate is also confirmed to co-produce a CTX-M-15 ESBL (extended-spectrum beta-lactamase) on the same resistance plasmid. The infectious disease team reviews available options. Which of the following represents the most pharmacologically appropriate definitive therapy for this patient?
A) Ceftazidime-avibactam at double the standard dose combined with meropenem, because the higher avibactam concentration will partially overcome NDM inhibitor resistance while meropenem provides a second mechanism of PBP inhibition that NDM cannot simultaneously hydrolyze at elevated carbapenem concentrations
B) Colistin (polymyxin E) monotherapy, because colistin's mechanism of outer membrane disruption is completely independent of beta-lactamase activity and bypasses all beta-lactam resistance mechanisms including NDM; its bactericidal activity does not require beta-lactam ring integrity
C) Cefiderocol monotherapy, because cefiderocol's siderophore mechanism delivers the drug directly to PBP3 without exposure to the periplasmic NDM enzyme, making NDM-mediated hydrolysis pharmacologically impossible for siderophore-conjugated cephalosporins
D) Aztreonam-avibactam, because aztreonam is intrinsically stable to hydrolysis by NDM (a class B metallo-beta-lactamase with no activity against the monocyclic aztreonam ring), and avibactam inhibits the co-produced CTX-M-15 ESBL (a class A serine enzyme) that would otherwise hydrolyze aztreonam; this combination exploits the mechanistic division between NDM's zinc-dependent activity and CTX-M's serine-dependent activity
E) Tigecycline plus aztreonam, because tigecycline's ribosomal inhibition provides bacteriostatic activity against the organism independent of beta-lactamase resistance, and aztreonam's anti-Pseudomonas spectrum provides complementary coverage against any Pseudomonas co-pathogen that may be present in the ICU patient
ANSWER: D
Rationale:
This case requires selecting therapy against an NDM-producing organism that co-produces CTX-M-15 ESBL and is resistant to all carbapenems, ceftazidime-avibactam, and meropenem-vaborbactam — the resistance profile that defines aztreonam-avibactam's clinical niche. The pharmacological rationale integrates three properties: first, aztreonam is intrinsically resistant to hydrolysis by NDM and all class B metallo-beta-lactamases because the monocyclic beta-lactam ring structure is a poor substrate for zinc-dependent water hydrolysis; second, CTX-M-15 is a class A serine ESBL that efficiently hydrolyzes aztreonam, which is why aztreonam monotherapy fails against this isolate; third, avibactam is a DBO inhibitor that forms a reversible covalent carbamylation with the CTX-M-15 catalytic serine, inactivating the co-produced enzyme that would otherwise destroy aztreonam. The combination therefore presents the organism with a drug (aztreonam) that NDM cannot hydrolyze, with the co-produced ESBL neutralized by avibactam. Ceftazidime-avibactam and meropenem-vaborbactam both fail because their beta-lactam partners (ceftazidime and meropenem) are hydrolyzed by NDM, and neither avibactam nor vaborbactam inhibits NDM.
Option A: Option A is incorrect; doubling avibactam dose does not confer NDM inhibitory activity — avibactam's failure against NDM is mechanistic (no catalytic serine to carbamylate), not a concentration-dependent issue; meropenem is hydrolyzed by NDM regardless of dose.
Option B: Option B is incorrect; while colistin is used in pan-resistant gram-negative infections as a salvage agent, colistin monotherapy for bacteremia with a pathogen sensitive to aztreonam-avibactam would be a suboptimal choice when a targeted pharmacologically rational combination exists; colistin also carries significant nephrotoxicity.
Option C: Option C is incorrect; cefiderocol does reach the periplasm via TonB-dependent transport and is then exposed to NDM in the periplasm — while cefiderocol is stable to NDM hydrolysis in vitro, it is not true that NDM hydrolysis is "pharmacologically impossible" for cefiderocol; additionally, cefiderocol has the CREDIBLE-CR Acinetobacter mortality signal and is positioned as salvage therapy, not first-line for NDM when aztreonam-avibactam is available.
Option E: Option E is incorrect; tigecycline has poor bactericidal activity for bacteremia, does not achieve adequate blood concentrations for Klebsiella bloodstream infections, and is not guideline-recommended for KPC or NDM bacteremia; aztreonam's indication in this combination would be for the NDM organism, not for Pseudomonas coverage.
7. A 68-year-old man is in the ICU on mechanical ventilation with ventilator-associated pneumonia. Bronchoalveolar lavage cultures grow carbapenem-resistant Acinetobacter baumannii (CRAB). Susceptibility testing confirms resistance to imipenem, meropenem, ceftazidime-avibactam, meropenem-vaborbactam, and all aminoglycosides. Molecular testing identifies OXA-23 as the carbapenemase. The isolate is reported as susceptible to sulbactam-durlobactam. An intern asks why this combination works when every other beta-lactam has failed. Which of the following best explains the mechanism?
A) Sulbactam has direct antibacterial activity against Acinetobacter baumannii through binding to PBP1 and PBP3 — an intrinsic property that distinguishes it from all other beta-lactamase inhibitors, which have no direct antibacterial activity; OXA-23 is a class D serine carbapenemase that hydrolyzes sulbactam in CRAB strains, rendering sulbactam inactive as monotherapy; durlobactam is a DBO (diazabicyclooctane) inhibitor that inhibits OXA-23 and other class D serine beta-lactamases, protecting sulbactam from hydrolysis and restoring its PBP-mediated antibacterial activity against CRAB
B) Sulbactam acts as a siderophore-conjugated beta-lactam that, like cefiderocol, uses TonB-dependent transporters for outer membrane penetration in CRAB strains; durlobactam inhibits the intracellular metallo-enzymes that would otherwise cleave the siderophore-sulbactam conjugate before it reaches its PBP targets in OXA-23-producing organisms
C) Durlobactam directly inhibits PBP2 of Acinetobacter baumannii with higher affinity than any currently available beta-lactam, while sulbactam functions solely as a beta-lactamase inhibitor protecting durlobactam from OXA-23 hydrolysis; the combination is active because durlobactam provides the bactericidal killing and sulbactam provides the enzymatic protection
D) Sulbactam-durlobactam is active because durlobactam chelates the zinc cofactors of OXA-23, converting it from a zinc-dependent carbapenemase to an inactive apoenzyme; sulbactam then reaches PBP1 and PBP3 through the zinc-depleted periplasm; this mechanism is specific to OXA-23 and would not apply to organisms producing KPC or NDM
E) Sulbactam-durlobactam bypasses OXA-23 resistance entirely through a non-beta-lactam mechanism; durlobactam disrupts Acinetobacter outer membrane integrity by inhibiting LPS (lipopolysaccharide) biosynthesis, and sulbactam enters the periplasm through the resulting membrane defects to bind PBP targets that are not accessible through normal porin channels
ANSWER: A
Rationale:
Sulbactam-durlobactam (Xacduro) represents the first FDA-approved targeted therapy specifically for CRAB infections, and its activity is built on a property of sulbactam that is unique among beta-lactamase inhibitors in clinical use. All other inhibitors — clavulanate, tazobactam, avibactam, vaborbactam — are pharmacologically inert against bacteria; they function only as enzyme inhibitors protecting a partner antibiotic. Sulbactam, by contrast, has intrinsic direct antibacterial activity against Acinetobacter baumannii through high-affinity binding to PBP1 and PBP3, the cell wall transpeptidases essential for Acinetobacter cell division and peptidoglycan elongation. This PBP-binding activity makes sulbactam itself a bactericidal agent against Acinetobacter, not merely a protective partner. The obstacle to using sulbactam against CRAB is that OXA-23 and OXA-58 (class D serine carbapenemases predominant in CRAB) hydrolyze sulbactam before it can accumulate to PBP-binding concentrations in the periplasm. Durlobactam, a DBO inhibitor structurally related to avibactam and relebactam, inhibits class A, C, and class D serine beta-lactamases including OXA-23 through reversible covalent carbamylation of the catalytic serine. By eliminating OXA-23-mediated sulbactam hydrolysis, durlobactam restores sulbactam's intrinsic antibacterial activity.
Option B: Option B is incorrect; sulbactam is not a siderophore conjugate and does not use TonB-dependent transporters; that mechanism belongs to cefiderocol.
Option C: Option C is incorrect; durlobactam does not itself bind PBP2 as an antibacterial agent; it is a beta-lactamase inhibitor; the antibacterial component of the combination is sulbactam, not durlobactam.
Option D: Option D is incorrect; OXA-23 is a class D serine carbapenemase, not a zinc-dependent enzyme; it does not have zinc cofactors; durlobactam inhibits it through serine carbamylation, not zinc chelation.
Option E: Option E is incorrect; durlobactam does not inhibit LPS biosynthesis or disrupt outer membrane integrity through a non-beta-lactam mechanism; it is a serine beta-lactamase inhibitor acting on the OXA-23 enzyme.
8. A 74-year-old man with a history of recurrent urinary tract infections is completing a course of ertapenem via OPAT for an ESBL-producing Klebsiella pneumoniae urosepsis. On day 6 he is admitted with new respiratory failure and fever. Chest imaging shows a new right lower lobe infiltrate. His prior hospitalization 3 weeks ago included a 4-day stay in a step-down unit. The clinical team diagnoses hospital-acquired pneumonia. Sputum Gram stain shows gram-negative rods. The team determines ertapenem must be replaced and asks which carbapenem should be chosen. Which of the following represents the most pharmacologically sound carbapenem selection for this patient's new clinical problem?
A) Continue ertapenem and increase the dose from 1 g to 2 g once daily, because the higher dose overcomes ertapenem's reduced anti-Pseudomonas activity at standard dosing through extended time above MIC that standard dosing cannot achieve
B) Switch to imipenem-cilastatin, which provides broader gram-negative coverage than ertapenem for hospital-acquired pneumonia while carrying the same anti-Pseudomonas activity as meropenem; seizure risk is not a clinical concern in this patient because he has no prior CNS history
C) Switch to meropenem, because it covers Pseudomonas aeruginosa — a major pathogen in hospital-acquired pneumonia, particularly in patients with recent hospitalizations — and has substantially lower seizure risk than imipenem-cilastatin due to its C-1 beta-methyl group's reduced GABA-A receptor interaction; in a 74-year-old patient with a new acute illness, minimizing seizure risk is clinically prudent even without a prior seizure history
D) Switch to ertapenem plus aztreonam, because combining ertapenem's ESBL coverage with aztreonam's gram-negative spectrum provides the anti-Pseudomonas activity missing from ertapenem monotherapy while maintaining the once-daily convenience of the existing OPAT line
E) Switch to doripenem, which carries no seizure risk because it is formulated without cilastatin and is the only carbapenem specifically approved by the FDA for hospital-acquired pneumonia due to its documented superior lung tissue penetration compared to all other carbapenems
ANSWER: C
Rationale:
Selecting the appropriate carbapenem for this patient requires integrating two distinct considerations. First, the coverage gap: ertapenem lacks reliable activity against Pseudomonas aeruginosa, and this patient's recent hospitalization (step-down unit 3 weeks ago) places him at risk for hospital-acquired Pseudomonas pneumonia — one of the most common and serious causes of nosocomial lower respiratory tract infection in patients with prior healthcare exposure. Ertapenem is categorically inadequate for hospital-acquired pneumonia when Pseudomonas is a plausible pathogen. Second, agent selection within the antipseudomonal carbapenems: meropenem is preferred over imipenem-cilastatin for several reasons in this 74-year-old patient. Meropenem's C-1 beta-methyl group confers substantially lower GABA-A receptor interaction than imipenem, producing meaningfully lower seizure risk. In an elderly patient with new acute illness, any reduction in CNS reserve is unpredictable; a seizure in a 74-year-old with acute respiratory failure carries high clinical consequences. Meropenem provides equivalent Pseudomonas coverage to imipenem without the seizurogenic liability.
Option A: Option A is incorrect; ertapenem's lack of anti-Pseudomonas activity is absolute — related to outer membrane porin affinity and efflux susceptibility in Pseudomonas — and cannot be overcome by dose escalation; there is no established dose at which ertapenem reliably covers Pseudomonas.
Option B: Option B is incorrect; imipenem-cilastatin does cover Pseudomonas, but the claim that seizure risk is not a concern because the patient has no prior CNS history understates the risk in a 74-year-old with acute illness; age and acute physiological stress are independent seizure risk factors, and the question of which antipseudomonal carbapenem is safer favors meropenem.
Option D: Option D is incorrect; ertapenem plus aztreonam is not a standard regimen; aztreonam covers gram-negative aerobes including Pseudomonas, but combining it with ertapenem creates an unnecessarily complex regimen when meropenem alone provides both ESBL and Pseudomonas coverage; aztreonam also provides no gram-positive or anaerobic coverage.
Option E: Option E is incorrect; doripenem is not the only FDA-approved carbapenem for hospital-acquired pneumonia; it does not carry "no seizure risk"; it does not have uniquely superior lung penetration compared to meropenem; and it is not the standard of care choice that would be distinguished here.
9. A 61-year-old man in the ICU has ventilator-associated pneumonia caused by carbapenem-resistant Acinetobacter baumannii (CRAB) producing OXA-23. The isolate is susceptible to both cefiderocol and sulbactam-durlobactam. An infectious disease fellow proposes cefiderocol as first-line therapy, citing its siderophore uptake mechanism and documented in vitro activity against CRAB. The attending physician agrees with cefiderocol's microbiological activity but raises a specific clinical concern that argues for preferring sulbactam-durlobactam as first-line. Which of the following best describes the clinical concern the attending is most likely raising?
A) Cefiderocol's siderophore mechanism requires adequate serum iron levels for drug activation; in critically ill ICU patients with sepsis-associated hypoferremia, cefiderocol cannot bind sufficient iron to form the ferric-drug complex required for TonB-dependent outer membrane transport, making it pharmacologically inactive in this patient population
B) The CREDIBLE-CR trial (a non-randomized descriptive phase 3 trial comparing cefiderocol to best available therapy in carbapenem-resistant infections) reported numerically higher all-cause mortality in the cefiderocol arm specifically within the Acinetobacter baumannii patient subgroup; this unexpected mortality signal — whose mechanism remains under investigation — argues for preferring sulbactam-durlobactam, the first FDA-approved targeted therapy for CRAB, as first-line monotherapy when it is a treatment option
C) Cefiderocol causes dose-dependent nephrotoxicity at the standard dosing regimen required for CRAB pneumonia; in ICU patients with sepsis-related acute kidney injury, cefiderocol accumulates to nephrotoxic concentrations that would cause irreversible renal failure, whereas sulbactam-durlobactam has no renal toxicity at any dose
D) Cefiderocol's activity against OXA-23-producing CRAB is limited because OXA-23 hydrolyzes the cephalosporin ring of cefiderocol in the periplasm after TonB-dependent transport; sulbactam-durlobactam is preferred because durlobactam inhibits OXA-23, preventing hydrolysis of both the durlobactam-sulbactam combination and the cephalosporin ring of any co-administered cefiderocol
E) Cefiderocol requires therapeutic drug monitoring (TDM) in critically ill patients because its siderophore moiety is metabolized at variable rates by ICU patients' residual cytochrome P450 activity; without TDM, cefiderocol cannot achieve reliable free drug concentrations above the MIC for CRAB, whereas sulbactam-durlobactam's pharmacokinetics are predictable without monitoring
ANSWER: B
Rationale:
The attending's concern is the CREDIBLE-CR trial mortality signal in the Acinetobacter subgroup — a specific, documented clinical finding that has altered the clinical positioning of cefiderocol for CRAB infections. The CREDIBLE-CR trial (Bassetti et al., Lancet Infectious Diseases, 2021) was a non-randomized, open-label, pathogen-focused descriptive phase 3 trial that compared cefiderocol to best available therapy (predominantly polymyxin-based regimens) in patients with serious carbapenem-resistant gram-negative infections. Although cefiderocol demonstrated microbiological activity across multiple resistant pathogens, all-cause mortality at 28 days was numerically higher in the cefiderocol arm compared to best available therapy specifically in the Acinetobacter baumannii subgroup. The mechanism of this mortality difference has not been definitively explained, and the finding did not result in withdrawal of cefiderocol's approval — but it introduced important clinical caution about using cefiderocol as first-line monotherapy for CRAB when a targeted alternative exists. Sulbactam-durlobactam received FDA approval specifically for CRAB infections and, in the absence of the CREDIBLE-CR mortality signal, represents the preferred first-line targeted option.
Option A: Option A is incorrect; cefiderocol does not require pre-formed ferric-drug complex from serum — it chelates environmental iron in situ; sepsis-associated hypoferremia does not render cefiderocol pharmacologically inactive, and this is not a recognized clinical limitation.
Option C: Option C is incorrect; the CREDIBLE-CR safety signal was a mortality signal in the Acinetobacter subgroup, not a nephrotoxicity signal; dose-dependent nephrotoxicity at standard CRAB dosing is not a recognized primary adverse effect profile of cefiderocol.
Option D: Option D is incorrect; cefiderocol is highly stable to hydrolysis by all beta-lactamase classes including OXA-23 — this is one of its defining pharmacological properties; the premise that OXA-23 hydrolyzes cefiderocol's cephalosporin ring is factually incorrect.
Option E: Option E is incorrect; cefiderocol does not undergo cytochrome P450 metabolism of its siderophore moiety; it does not require therapeutic drug monitoring as a standard practice; this is a fabricated pharmacokinetic concern.
10. A 55-year-old woman is in the ICU with bacteremia caused by a Klebsiella pneumoniae isolate with carbapenem MICs (minimum inhibitory concentrations) in the resistant range. A comprehensive carbapenemase PCR panel returns negative for KPC, NDM, VIM, IMP, and OXA-48. Susceptibility testing shows the isolate is susceptible to ceftazidime-avibactam with a low MIC. Whole-genome sequencing reveals mutations causing loss of OmpK35 and OmpK36 porin expression, along with high-level overexpression of a chromosomal CTX-M-15 ESBL (extended-spectrum beta-lactamase). The infectious disease team proceeds with ceftazidime-avibactam as definitive therapy. A resident asks why ceftazidime-avibactam works when the isolate is carbapenem-resistant. Which of the following best explains the mechanism?
A) Ceftazidime-avibactam is active because ceftazidime, unlike carbapenems, uses the OmpF (outer membrane protein F) porin rather than OmpK35 or OmpK36 for outer membrane penetration; loss of OmpK35 and OmpK36 does not affect ceftazidime entry, making ceftazidime-avibactam pharmacokinetically unaffected by this isolate's porin mutations
B) Ceftazidime-avibactam is active because avibactam inhibits the OmpK35/OmpK36 regulatory repressor proteins, restoring porin expression in this isolate; once porins are re-expressed, ceftazidime re-enters the periplasm normally, and the CTX-M-15 ESBL is irrelevant because ceftazidime is inherently ESBL-resistant
C) Ceftazidime-avibactam is active because carbapenem resistance in this isolate is mediated by KPC at concentrations too low for standard PCR detection; avibactam inhibits this sub-threshold KPC, and ceftazidime is pharmacokinetically superior to carbapenems for this organism because it is not subject to MexAB-OprM efflux in Klebsiella
D) Ceftazidime-avibactam is active because ceftazidime binds all five Klebsiella PBP subtypes simultaneously at the concentrations achieved with standard dosing, saturating all cell wall synthesis sites before CTX-M-15 can hydrolyze the drug; porin loss is irrelevant because ceftazidime achieves sufficient cell wall disruption before periplasmic equilibration is complete
E) Ceftazidime-avibactam is active because carbapenem resistance in this isolate is non-carbapenemase-mediated — arising from synergy of porin loss with CTX-M-15 ESBL overexpression; avibactam inhibits the CTX-M-15 ESBL (a class A serine enzyme), eliminating the enzymatic hydrolysis component of resistance; with the ESBL neutralized, ceftazidime reaches its PBP targets at adequate concentrations despite the reduced porin-mediated entry
ANSWER: E
Rationale:
This case illustrates the non-carbapenemase CRE phenotype and how avibactam's enzyme inhibitory spectrum makes ceftazidime-avibactam active even when carbapenems are not. The isolate's carbapenem resistance results from the synergy of two mechanisms: OmpK35/OmpK36 porin loss reduces the rate of carbapenem influx into the periplasm, and CTX-M-15 ESBL overexpression hydrolyzes the reduced amount of carbapenem that does enter. Neither mechanism alone produces high-level carbapenem resistance, but together they raise carbapenem MICs to the resistant range. This non-carbapenemase resistance mechanism is carbapenemase-PCR-negative because no carbapenemase gene is present. Ceftazidime-avibactam's activity is explained by avibactam's inhibition of CTX-M-15, a class A serine ESBL that avibactam inhibits through reversible covalent DBO carbamylation of the catalytic serine. With CTX-M-15 inhibited, the enzymatic component of resistance is eliminated; the remaining porin-loss component reduces ceftazidime entry but does not prevent bactericidal concentrations from accumulating in the periplasm because ceftazidime's efficacy (like all beta-lactams) is time-dependent and sustained exposure even at reduced periplasmic concentrations can achieve killing of a susceptible organism.
Option A: Option A is incorrect; ceftazidime and carbapenems both depend on OmpK35/OmpK36 (and related porins) for outer membrane penetration in Klebsiella; ceftazidime does not preferentially use an unaffected alternative porin; and ceftazidime is not inherently ESBL-resistant — CTX-M ESBLs hydrolyze ceftazidime efficiently.
Option B: Option B is incorrect; avibactam inhibits beta-lactamases (serine enzymes), not porin regulatory proteins; it has no effect on porin gene expression; porin restoration is not the mechanism.
Option C: Option C is incorrect; the PCR-negative result reflects genuine absence of KPC — PCR panels for KPC are sensitive and do not miss KPC at clinically relevant expression levels; MexAB-OprM is a Pseudomonas efflux system not expressed in Klebsiella.
Option D: Option D is incorrect; ceftazidime does not simultaneously saturate all five PBP subtypes before hydrolysis occurs; CTX-M-15 hydrolyzes ceftazidime efficiently and this is exactly why avibactam is needed; the pharmacodynamic argument described is not mechanistically valid.
11. A 66-year-old woman with CrCl 22 mL/min is started on imipenem-cilastatin for a gram-negative intra-abdominal infection. On day 3 she develops a witnessed tonic-clonic seizure and her creatinine rises from 1.8 to 3.1 mg/dL over 24 hours. Review of her chart reveals that her imipenem-cilastatin dose had not been adjusted for her renal impairment and she had been receiving the standard dose intended for normal renal function. The nephrology and neurology teams both consult. Which of the following best explains the distinct pharmacological mechanisms responsible for each of the two adverse events in this patient?
A) Both adverse events share a single mechanism: imipenem accumulation in renal tubular cells causes direct proximal tubular necrosis, which reduces renal clearance of imipenem's CNS-active metabolite; the CNS-active metabolite then accumulates to seizurogenic concentrations in a feedforward loop driven by the renal injury itself
B) The seizure was caused by cilastatin accumulation; cilastatin is renally cleared and accumulates in renal impairment, where it competes with GABA at the GABA-A receptor; the AKI was caused by imipenem direct nephrotoxicity through mitochondrial respiratory chain inhibition in proximal tubular cells at the elevated concentrations produced by renal impairment
C) The seizure was caused by imipenem activating voltage-gated sodium channels in a use-dependent manner at high plasma concentrations produced by renal accumulation; the AKI was caused by cilastatin inhibiting the organic anion transporters that normally clear endogenous uremic toxins, leading to tubular toxin accumulation and secondary nephrotoxicity
D) The seizure resulted from imipenem accumulation due to inadequate renal dose adjustment, producing elevated CNS drug concentrations that antagonize GABA-A (gamma-aminobutyric acid type A) receptors at the picrotoxin-binding site, lowering the seizure threshold; the AKI resulted from inadequate cilastatin dosing (or failure to adjust the cilastatin component proportionally), allowing DHP-I (dehydropeptidase I) to hydrolyze imipenem in the renal tubule and generate nephrotoxic ring-opened metabolites that damage the proximal tubular epithelium
E) Both adverse events resulted from the same root cause of underdosing: the reduced imipenem dose in renal impairment produced subtherapeutic concentrations, allowing bacterial endotoxin release from inadequately killed organisms; endotoxin crossed the blood-brain barrier causing seizures and simultaneously triggered complement-mediated acute tubular injury producing AKI
ANSWER: D
Rationale:
This case presents two simultaneous adverse events from imipenem-cilastatin, each with a distinct pharmacological mechanism that the dose-adjustment failure amplified in different ways. The seizure mechanism: imipenem and its ring-opened products antagonize GABA-A receptors at the picrotoxin-binding site within the chloride channel, reducing inhibitory GABAergic neurotransmission and lowering the seizure threshold. This effect is concentration-dependent — higher plasma concentrations produce greater GABA-A receptor occupancy and greater seizure risk. In a patient with CrCl 22 mL/min, failure to dose-adjust imipenem results in drug accumulation to plasma concentrations substantially above those achieved in patients with normal renal function, amplifying the GABA-A antagonism to a clinically seizurogenic level. The AKI mechanism: cilastatin inhibits DHP-I (dehydropeptidase I) on the proximal renal tubular brush border, preventing imipenem hydrolysis to its nephrotoxic ring-opened metabolites. In renal impairment, if the cilastatin component is not proportionally adjusted alongside the imipenem dose, the ratio of imipenem to cilastatin reaching the tubular brush border may be suboptimal — allowing DHP-I to generate nephrotoxic metabolites that damage the proximal tubular epithelium. The two mechanisms — CNS GABA-A antagonism from imipenem accumulation and renal proximal tubular injury from cilastatin-unprotected DHP-I hydrolysis — are independent and pharmacologically distinct.
Option A: Option A is incorrect; imipenem does not cause proximal tubular necrosis through a direct toxicity mechanism independent of DHP-I metabolites; the renal injury mechanism is metabolite-mediated, not direct imipenem nephrotoxicity.
Option B: Option B is incorrect; cilastatin does not interact with GABA-A receptors and has no recognized CNS activity; the seizure mechanism is attributable to imipenem and its hydrolysis products, not cilastatin.
Option C: Option C is incorrect; imipenem does not activate voltage-gated sodium channels; cilastatin does not inhibit organic anion transporters involved in uremic toxin clearance; these are fabricated mechanisms.
Option E: Option E is incorrect; inadequate bacterial killing producing endotoxin release is not the pharmacological mechanism of imipenem-associated seizures or AKI; these are direct drug pharmacology adverse effects, not indirect consequences of subtherapeutic dosing.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.